-

01:34:19 AM

RAIN Stock News

RAIN - Rain Oncology Inc

01/31/23 8:00 AM

Nasdaq : RAIN

conferenceslow float

Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference

Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p53, today

RHEA-AI

neutral

01/23/23 8:00 AM

Nasdaq : RAIN

clinical triallow float

Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology

– Intermittent dosing of milademetan, an inhibitor of the p53-MDM2 complex, potentially exhibits an avenue to address historical issues with cytopenias with this class of compounds– – Phase 1 data in advanced dedifferentiated liposarcoma provides foundation for the registrational Phase 3 MANTRA

RHEA-AI

negative

12/29/22 8:00 AM

Nasdaq : RAIN

low float

Rain Therapeutics Inc. Announces Name Change to Rain Oncology Inc.

Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that

RHEA-AI

neutral

12/27/22 8:00 AM

Nasdaq : RAIN

conferenceslow float

Rain Therapeutics to Participate in the 41st Annual J.P. Morgan Health Care Conference

Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates

RHEA-AI

neutral

11/23/22 8:00 AM

Nasdaq : RAIN

low float

Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium

Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates

RHEA-AI

neutral

11/18/22 8:00 AM

Nasdaq : RAIN

conferenceslow float

Rain Therapeutics to Participate in Piper Sandler’s 34th Annual Healthcare Conference

Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates

RHEA-AI

neutral

11/17/22 1:05 PM

Nasdaq : RAIN

low float

Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual Meeting

Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates

RHEA-AI

neutral

11/14/22 8:00 AM

Nasdaq : RAIN

conferenceslow float

Rain Therapeutics to Participate in H.C. Wainwright’s 3rd Annual Precision Oncology Virtual Conference

Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates

RHEA-AI

neutral

11/10/22 4:05 PM

Nasdaq : RAIN

earningslow float

Rain Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

– End of third quarter cash position of $90.7 million excludes the recent $50 million registered offering, and together, provide a cash runway into 2025 – – Phase 3 pivotal MANTRA trial topline data now anticipated in first quarter of 2023 – – Phase 2 MANTRA-2 trial preliminary interim data

RHEA-AI

neutral

11/04/22 8:00 AM

Nasdaq : RAIN

offeringlow float

Rain Therapeutics Announces $50 Million Registered Offering of Common Stock

Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of

RHEA-AI

neutral

1 2 3 4 5 6 Next

RAIN Data

IndustryMedicinal and Botanical Manufacturing
Websitewww.rainthera.com
Security nameRain Oncology Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees44

About Rain Oncology Inc

Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to RAIN-32, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.